1. Home
  2. TSLX vs AUPH Comparison

TSLX vs AUPH Comparison

Compare TSLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$19.23

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.23

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
AUPH
Founded
2010
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
TSLX
AUPH
Price
$19.23
$14.23
Analyst Decision
Buy
Buy
Analyst Count
10
4
Target Price
$23.50
$17.25
AVG Volume (30 Days)
745.1K
836.9K
Earning Date
02-12-2026
02-26-2026
Dividend Yield
10.66%
N/A
EPS Growth
N/A
N/A
EPS
1.81
0.55
Revenue
$449,055,000.00
$265,808,000.00
Revenue This Year
N/A
$21.76
Revenue Next Year
N/A
$16.45
P/E Ratio
$10.62
$25.87
Revenue Growth
N/A
20.62
52 Week Low
$18.58
$6.55
52 Week High
$25.17
$16.54

Technical Indicators

Market Signals
Indicator
TSLX
AUPH
Relative Strength Index (RSI) 25.63 38.73
Support Level $19.63 $14.21
Resistance Level $20.35 $14.66
Average True Range (ATR) 0.59 0.45
MACD -0.21 -0.02
Stochastic Oscillator 3.85 3.88

Price Performance

Historical Comparison
TSLX
AUPH

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: